Reuters logo
Drug-maker Valeant eyes small and large M&A deals
October 31, 2013 / 1:20 PM / in 4 years

Drug-maker Valeant eyes small and large M&A deals

(Reuters) - Canada’s Valeant Pharmaceuticals International Inc (VRX.TO) said on Thursday that it sees small, cash-based acquisitions likely in the near term, but is also interested in a “merger of equals” involving a swap of equity.

Chief Executive Michael Pearson said he thinks such a merger will happen, but is unsure of the timing.

Reporting by Rod Nickel in Winnipeg, Manitoba; Editing by Gerald E. McCormick

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below